Apogee Therapeutics, Inc. Share Price
NASDAQ: APGE | Mid CapApogee Therapeutics, Inc. Stock Performance
Open $134.49 | Prev. Close $134.50 | Circuit Range N/A |
Day Range $134.48 - $134.67 | Year Range $34.35 - $134.67 | Volume 38,717 |
Average Traded $134.57 |
Apogee Therapeutics, Inc. Share Price Today
As of 10 August 2026, Apogee Therapeutics, Inc.'s share price is $134.83. The stock opened at $134.49, compared to its previous close of $134.50. During today's trading session, Apogee Therapeutics, Inc.'s share price traded between $134.48 and $134.67, with an average price of $134.57. Over the past 52 weeks, the stock has recorded a high of $134.67 and a low of $34.35. In terms of performance, Apogee Therapeutics, Inc.'s share price has risen by 92.59% over the last six months and is up 270.72% on a year-on-year basis.
Apogee Therapeutics, Inc. Share Price Chart
Apogee Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $8.18B | PE Ratio (TTM) -31.95 | Dividend Yield N/A |
EPS (TTM) $-4.22 | Revenue (TTM) N/A | Return On Equity (TTM) N/A |
Profit Margin N/A | Debt to Equity N/A | Quarterly Earnings Growth YoY -32.65% |
Apogee Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Apogee Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Apogee Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $134.12 | $134.83 | +0.55% |
Jul 2026 | $132.80 | $134.09 | +1.05% |
Jun 2026 | $80.70 | $132.70 | +61.44% |
May 2026 | $83.86 | $82.20 | -0.86% |
Apr 2026 | $85.00 | $82.91 | -1.53% |
Mar 2026 | $67.36 | $84.20 | +20.27% |
Feb 2026 | $64.00 | $70.01 | +6.96% |
Jan 2026 | $75.63 | $65.45 | -13.32% |
Dec 2025 | $70.83 | $75.51 | +4.72% |
Nov 2025 | $57.40 | $72.11 | +27.33% |
Oct 2025 | $39.85 | $56.63 | +42.25% |
Sep 2025 | $36.34 | $39.81 | +9.46% |
APGE Share Price FAQs
What is Apogee Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Apogee Therapeutics, Inc. stock?
What is APGE's market capitalisation today?
What is APGE's net income for the last quarter?
What is the 5 year returns of APGE?
What is the high & low stock price of APGE today?
Can I buy APGE shares in India?